Shopping Cart
- Remove All
- Your shopping cart is currently empty
SIAIS562055, a potent cereblon-based SOS1PROTAC, exhibits a dissociation constant (Kd) of 95.9 nM. It effectively degrades SOS1 and inhibits the downstream ERK pathway. SIAIS562055 disrupts the interaction between KRASG12C or KRASG12D and SOS1, with IC50 values of 95.7 nM and 134.5 nM, respectively. This compound demonstrates strong anticancer activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | SIAIS562055, a potent cereblon-based SOS1PROTAC, exhibits a dissociation constant (Kd) of 95.9 nM. It effectively degrades SOS1 and inhibits the downstream ERK pathway. SIAIS562055 disrupts the interaction between KRASG12C or KRASG12D and SOS1, with IC50 values of 95.7 nM and 134.5 nM, respectively. This compound demonstrates strong anticancer activity. |
Targets&IC50 | SOS1:95.9 nM (Kd) |
In vitro | SIAIS562055 (10-1000 nM; 24 hours) consistently demonstrates the degradation of SOS1 and the inhibition of the downstream ERK pathway, exhibiting excellent antiproliferative activity. |
In vivo | SIAIS562055 administered at a dosage of 20-50 mg/kg via intraperitoneal injection daily for a continuous duration of three weeks demonstrated significant antitumor efficacy in xenografts bearing KRAS mutations. |
Molecular Weight | 918.12 |
Formula | C49H62F3N7O5S |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.